Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers
Carolina Mora-SolanoYi WenHuifang HanJianjun ChenAnita S. ChongMichelle L. MillerRebecca R. PompanoJoel H. Collier
72
Citation
58
Reference
10
Related Paper
Citation Trend
Keywords:
Active immunotherapy
In this editorial, the author considers the human models for research on cancer immunotherapy. He distinguishes between trials which have given a direct demonstration of the action of immunotherapy, in which the effect of this treatment has been compared to therapeutic abstention, and those which have shown an indirect proof of its action and in which immunotherapy is compared to chemotherapy of which the effect is known, or in which the combination of chemotherapy and immunotherapy is compared with the same chemotherapy applied alone. The author concludes with methodological and ethical considerations about clinical trials applied to active immunotherapy.
Active immunotherapy
Cancer Immunotherapy
Cite
Citations (2)
Immunotherapy has brought, arguably, the biggest advances in cancer treatment in recent years. Cancer immunotherapy can be divided into active and passive approaches. For example, vaccines are an active immunotherapy where the patient’s own immune system is mobilized to fight malignancy. On the other hand, passive immunotherapy relies on administering the effector arms of the immune system like antibodies or T cells.
Active immunotherapy
Cancer Immunotherapy
Cite
Citations (3)
Active immunotherapy
Cite
Citations (20)
Abstract The prognosis of patients with malignant glioma is poor in spite of multimodal treatment approaches consisting of neurosurgery, radiochemotherapy and maintenance chemotherapy. Among innovative treatment strategies like targeted therapy, antiangiogenesis and gene therapy approaches, immunotherapy emerges as a meaningful and feasible treatment approach for inducing long‐term survival in at least a subpopulation of these patients. Setting up immunotherapy for an inherent immunosuppressive tumor located in an immune‐privileged environment requires integration of a lot of scientific input and knowledge of both tumor immunology and neuro‐oncology. The field of immunotherapy is moving into the direction of active specific immunotherapy using autologous dendritic cells (DCs) as vehicle for immunization. In the translational research program of the authors, the whole cascade from bench to bed to bench of active specific immunotherapy for malignant glioma is covered, including proof of principle experiments to demonstrate immunogenicity of patient‐derived mature DCs loaded with autologous tumor lysate, preclinical in vivo experiments in a murine orthotopic glioma model, early phase I/II clinical trials for relapsing patients, a phase II trial for patients with newly diagnosed glioblastoma (GBM) for whom immunotherapy is integrated in the current multimodal treatment, and laboratory analyses of patient samples. The strategies and results of this program are discussed in the light of the internationally available scientific literature in this fast‐moving field of basic science and translational clinical research.
Active immunotherapy
Translational Research
Bench to bedside
Cite
Citations (95)
Bei der Immuntherapie von Krebserkrankungen wird zwischen passiven und aktiven Strategien unterschieden. Die passive Immuntherapie, z.B. der therapeutische Einsatz von monoklonalen Antikörpern, oder im weitesten Sinn auch von anderen immunologischen Effektormolekülen, wie z.B. Interferon-alpha, ist längst klinisch etabliert. Der zunehmende Erfolg der passiven Immuntherapie belegt, dass das Immunsystem erfolgreich gegen Krebserkrankungen eingesetzt werden kann. Der logische nächste Schritt ist es deshalb eine Weiterentwicklung zur aktiven Immuntherapie, also zur «Impfung gegen Krebs». Diese Übersichtsarbeit konzentriert sich auf die aktive Immuntherapie gegen Krebsleiden und versucht den heutigen Stand der Forschung und des klinischen Fortschrittes darzustellen. Obwohl heute noch keine aktive Immuntherapie außerhalb von klinischen Studien empfohlen werden kann, sind die Daten vielversprechend und es ist zu erwarten, dass einige Impfstoffe demnächst zur Verfügung stehen werden.
Active immunotherapy
Cancer Immunotherapy
Cite
Citations (0)
The primary goal of cancer vaccines is to activate the immune system to eliminate tumor cells without affecting normal tissues. There are two major approaches to cancer immunotherapy: active immunotherapy and passive immunotherapy (Fig. 1). Active immunotherapy involves the delivery of a substance designed to elicit an immune reaction. The host's immune system must first recognize and then respond to the target. Passive immunotherapy involves the delivery of a substance with intrinsic immunological activity such as an antibody or activated lymphocytes. This chapter focuses on the former approach.
Active immunotherapy
Cancer Immunotherapy
Cite
Citations (1)
Active immunotherapy
Active immunization
Cancer Immunotherapy
Adoptive Cell Transfer
Cite
Citations (11)
Abstract In this seminar, we describe 1) the immunogen TAA used for lung cancer immunotherapy and the immunogen TAA used for colon cancer immunotherapy, 2) the methods used in the administration of these immunogens in clinical trials of specific active TAA immunotherapy, 3) the results of clinical trials of specific active immunotherapy for lung cancer and for colon cancer patients, 4) the results of immune response monitoring evaluations, and what they indicate, and 5) the way in which certain drugs, selected for their action in the immune system, may be synergistic with specific active TAA immunotherapy, in combination therapy, especially for resected patients of later stages.
Immunogen
Active immunotherapy
Cancer Immunotherapy
Cite
Citations (10)
Abstract Conflicts amongst reports concerning the efficacy of both nonspecific and specific attempts at immunotherapy may be ascribed to different animal models utilizing tumors of different immunogenicity. We have selected the B16 mouse melanoma model as the example of a spontaneously occurring neoplasm that is histocompatible with the host and does have tumor‐associated antigens. Attempts to alter tumor growth or survival with nonspecific active immunotherapy as well as with specific active immunotherapy were not successful. Nonspecific active pre‐immunization failed to alter tumor take or growth. Specific active immunotherapy both with and without adjuvant did decrease tumor take and prolong host survival. The effects were increasingly documented at lower tumor cell inoculums and became less apparent with increase in the tumor cell challenge.
Active immunotherapy
Active immunization
Neoplasm
Cite
Citations (17)
PROBLEM: The immunological mechanism of an effective immunotherapy with paternal lymphocytes for unexplained recurrent spontaneous abortion (RSA) is not yet clear. Previous studies revealed that progesterone plays an important role in maintaining normal pregnancy and lower expression of progesterone receptor (PGR) on lymphocytes was found in RSA. Therefore, it was of interest to investigate whether immunotherapy for RSA would be able to enhance the expression of PGR on lymphocytes of RSA. METHOD: PGR expression on lymphocytes was analyzed with indirect immunofluorescence using flow cytometry. RESULTS: There was no change of PGR expression on PBL of RSA between pre‐ and post‐immunotherapy ( P > 0.05), while in the presence of 10.0 ug/ml progesterone for 24 h, PGR expressed on PBL on post‐immunotherapy was increased significantly as compared with that of pre‐immunotherapy in successful cases ( P < 0.05) and decreased in abortive cases ( P < 0.05). Most PGR was expressed on both CD4 + and CD8 + lymphocyte subsets. In successful cases, CD8 + PGR + subset of post‐immunotherapy was found to be increased significantly ( P < 0.05) in comparison with that of pre‐immunotherapy. CONCLUSION: The data in the present study suggest that immunotherapy for RSA induced a higher expression of PGR on progesterone‐treated lymphocytes, which may be involved in successful pregnancy.
Active immunotherapy
Progesterone receptor
Cite
Citations (49)